Friends of Cancer Research Virtual Meeting

Shaping the Future of Emerging Immunotherapies and Cell Therapies

Thank You to all that Attended!
Click Here to Watch in Full
Click HERE for the meeting white paper

Thursday, February 11, 2021
12:00PM EST – 1:00PM EST

Friends of Cancer Research (Friends) is proud to announce a new virtual meeting building on our previous work, Shaping the Future of Emerging Immunotherapies and Cell Therapies. The virtual meeting will include impactful discussions from leaders in cancer research and drug development to discuss the changing regulatory landscape of cell, gene, and immuno-oncology therapies. The full meeting objectives are included below:

• Characterize current challenges and recommendations for consistent capture of novel toxicities in early clinical development
• Discuss current regulatory paradigms and opportunities to facilitate the development of emerging cell therapies and other complex immunotherapies
• Discuss longitudinal data collection needs for assessing duration of benefit and toxicities
• Discuss near-term and long-term objectives to facilitate development and sustainability of cell therapies

For more information, scroll through below for the full agenda.

Final Agenda

Opening Remarks

• Ellen Sigal, Friends of Cancer Research

Opening Keynote

• Dr. Ned Sharpless, Director, National Cancer Institute (NCI)

Panel 1: Characterizing Unique Toxicities in Clinical Development—Data Collection Alignment

• Bruce McCall, Genentech (Moderator)
• Meredith Chuk, Center for Drug Evaluation & Research, FDA
• PK Morrow, Amgen
• Marcelo Pasquini, Medical College of Wisconsin

Panel 2:  Shaping the Future of Cell Therapies – 2021 and Beyond

• Anna Edney, Bloomberg News (Moderator)
• Jennifer Malin, UnitedHealth Group
• Peter Marks, Center for Biologics Evaluation & Research, FDA
• Mark McClellan, Duke-Margolis Center for Health Policy
• Renu Vaish, Kite, A Gilead Company

Concluding Remarks

• Jeff Allen, Friends of Cancer Research